Axsome Says Symbravo Hits Main Purpose In Late-Stage Migraine Trial In Sufferers Experiencing Insufficient Response To Generally Used Medication – Axsome Therapeutics (NASDAQ:AXSM)

On Monday, Axsome Therapeutics, Inc. AXSM introduced that the EMERGE Section 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in sufferers experiencing insufficient response to oral CGRP inhibitors (mostly used medication for migraine) met its major endpoint.

Symbravo demonstrated statistically considerably higher migraine remedy response than oral CGRP inhibitors, as measured by the Migraine Remedy Optimization Questionnaire (mTOQ-4) (5.2 versus 2.8, p<0.001).

Additionally Learn: Axsome’s AXS-05 In Alzheimer’s Agitation May Be Billion Greenback Alternative, Says Analyst

Within the trial, Symbravo quickly and considerably improved migraine ache and most bothersome signs.

Statistically considerably higher proportions of sufferers achieved scientific response on the 2-hour ache freedom, sustained ache freedom, skill to return to regular actions, and skill to plan every day actions mTOQ-4 objects with Symbravo in comparison with oral CGRP inhibitors:

• Ache freedom inside 2 hours for many assaults was reported half the time or extra by 47.9% of sufferers after remedy with Symbravo, in comparison with 1.0% of sufferers after remedy with oral CGRPs.
• Sustained aid of migraine ache for a minimum of 24 hours following a single dose of medicine was reported half the time or extra by 47.9% of sufferers after remedy with Symbravo, in comparison with 16.7% of sufferers after remedy with oral CGRPs.
• The flexibility to rapidly return to regular actions after taking their medicine was reported half the time or extra by 51.0% of sufferers after remedy with Symbravo, in comparison with 11.5% of sufferers after remedy with oral CGRPs.
• The proportion of sufferers who reported being snug sufficient with their medicine to have the ability to plan every day actions half the time or extra was 63.5% after remedy with Symbravo, in comparison with 26.0% after remedy with oral CGRPs.

Value Motion: AXSM inventory is down 4.82% at $131.12 ultimately examine Monday.

Learn Subsequent: